Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 2/20 | 0.42 |
| ▸ | SI | P14410 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055707 | 0.82 | KDM4E (0.62) | KDM4ESLC18A3SIGMAR1L3MBTL1AOC3 | |
| SCHEMBL31269802 | 0.82 | KDM4E (0.62) | KDM4EL3MBTL1MGAMSIAOC3 | |
| SCHEMBL31270029 | 0.82 | KDM4E (0.62) | KDM4EL3MBTL1MGAMSIAOC3 | |
| SCHEMBL10877574 | 0.81 | KDM4E (0.88) | KDM4EL3MBTL1 | |
| SCHEMBL10877567 | 0.81 | KDM4E (0.88) | KDM4EL3MBTL1 | |
| SCHEMBL31269959 | 0.80 | KDM4E (0.71) | KDM4EL3MBTL1MGAMSIAOC3 | |
| SCHEMBL7056462 | 0.79 | ADRB3 (0.44) | KDM4E | |
| SCHEMBL8076934 | 0.79 | ADRB3 (0.44) | KDM4E | |
| SCHEMBL7052344 | 0.78 | ADRB3 (0.43) | KDM4E | |
| SCHEMBL13799342 | 0.78 | ADRB3 (0.43) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0940387-B1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2003-05-07 | — | — | EP | claimed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | claimed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | claimed |
| US-7544841-B2 | Production method of phenylethanolamine compound, and its intermediate | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | MITSUBISHI PHARMA CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | disclosed |
| WO-2000000459-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE TRANS-CYCLOHEXYLAMINE COMPOUNDS | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-01-06 | — | — | WO | disclosed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | PNMT, COMT, CYP2E1 | KDM4E 4259/4885SLC18A3 280/4885SIGMAR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.